Clinical Trial: A Study of IBI3032 in Chinese Participants With Overweight or Obesity

U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07170319) titled 'A Study of IBI3032 in Chinese Participants With Overweight or Obesity' on Sept. 07.

Brief Summary: This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Overweight or Obesity

Intervention: DRUG: IBI3032

IBI3032. Method of administration: oral, fasted adminis...